Literature DB >> 8089062

Itraconazole cyclodextrin solution--effective treatment for HIV-related candidosis unresponsive to other azole therapy.

J D Cartledge, J Midgley, M Youle, B G Gazzard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8089062     DOI： 10.1093/jac/33.5.1071

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  11 in total

1.  Evaluation of the fungitest kit by using strains from human immunodeficiency virus-infected patients: study of azole drug susceptibility.

Authors:  F Witthuhn; D Toubas; I Béguinot; D Aubert; C Rouger; G Remy; J M Pinon
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 2.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

3.  Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis.

Authors:  J D Cartledge; J Midgely; B G Gazzard
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

4.  In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.

Authors:  M Ruhnke; A Schmidt-Westhausen; M Trautmann
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 5.  Clinical experience with itraconazole in systemic fungal infections.

Authors:  M Boogaerts; J Maertens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Current management of fungal infections.

Authors:  J F Meis; P E Verweij
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.

Authors:  Andreas H Groll; Lauren Wood; Maureen Roden; Diana Mickiene; Christine C Chiou; Ellen Townley; Luqman Dad; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.

Authors:  J V Martinez-Suarez; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 9.  Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment.

Authors:  Markus Ruhnke
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066).

Authors:  J Thoden; A Potthoff; J R Bogner; N H Brockmeyer; S Esser; K Grabmeier-Pfistershammer; B Haas; K Hahn; G Härter; M Hartmann; C Herzmann; J Hutterer; A R Jordan; C Lange; S Mauss; D Meyer-Olson; F Mosthaf; M Oette; S Reuter; A Rieger; T Rosenkranz; M Ruhnke; B Schaaf; S Schwarze; H J Stellbrink; H Stocker; A Stoehr; M Stoll; C Träder; M Vogel; D Wagner; C Wyen; C Hoffmann
Journal:  Infection       Date:  2013-09-14       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.